JP2011528040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528040A5 JP2011528040A5 JP2011518851A JP2011518851A JP2011528040A5 JP 2011528040 A5 JP2011528040 A5 JP 2011528040A5 JP 2011518851 A JP2011518851 A JP 2011518851A JP 2011518851 A JP2011518851 A JP 2011518851A JP 2011528040 A5 JP2011528040 A5 JP 2011528040A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidin
- ylamino
- pyridin
- benzamide
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxy, hydroxy Chemical group 0.000 claims description 887
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 152
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- 150000001875 compounds Chemical class 0.000 claims description 87
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 38
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 36
- 125000001188 haloalkyl group Chemical group 0.000 claims description 33
- 125000005843 halogen group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 27
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 12
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 12
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 12
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
- 125000001589 carboacyl group Chemical group 0.000 claims description 12
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004283 imidazolin-2-yl group Chemical group [H]N1C(*)=NC([H])([H])C1([H])[H] 0.000 claims description 12
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 12
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims description 12
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims description 12
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 12
- 125000006225 propoxyethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000004290 pyrazolidin-3-yl group Chemical group [H]N1N([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000004291 pyrazolin-3-yl group Chemical group [H]C1([H])N=NC([H])(*)C1([H])[H] 0.000 claims description 12
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 11
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000002912 morpholin-4-ylsulfonyl group Chemical group O1C([H])([H])C([H])([H])N(S(=O)(=O)[*])C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 8
- 125000005110 aryl thio group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 8
- 125000004468 heterocyclylthio group Chemical group 0.000 claims description 8
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000004282 imidazolidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])N([H])C1([H])* 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 230000004761 fibrosis Effects 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000003106 haloaryl group Chemical group 0.000 claims description 5
- OESFBXUFIOULLI-UHFFFAOYSA-N 3-[2-[4-(hydroxycarbamoyl)anilino]pyrimidin-4-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxylic acid Chemical compound CC=1N=C2C=C(C(O)=O)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 OESFBXUFIOULLI-UHFFFAOYSA-N 0.000 claims description 4
- CKLAVVIGLANTRR-UHFFFAOYSA-N 3-[2-[4-[(2-aminophenyl)carbamoyl]anilino]pyrimidin-4-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxylic acid Chemical compound CC=1N=C2C=C(C(O)=O)C=CN2C=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N CKLAVVIGLANTRR-UHFFFAOYSA-N 0.000 claims description 4
- BBISEGSBCVOASE-UHFFFAOYSA-N 4-[[4-(7-cyano-2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=C(C#N)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 BBISEGSBCVOASE-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- MPNKIHDEASYURU-UHFFFAOYSA-N methyl 3-[2-[4-(hydroxycarbamoyl)anilino]pyrimidin-4-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxylate Chemical compound CC=1N=C2C=C(C(=O)OC)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 MPNKIHDEASYURU-UHFFFAOYSA-N 0.000 claims description 4
- HFXAVTRLAAABKN-UHFFFAOYSA-N methyl 3-[2-[4-[(2-aminophenyl)carbamoyl]anilino]pyrimidin-4-yl]-2-methylimidazo[1,2-a]pyridine-7-carboxylate Chemical compound CC=1N=C2C=C(C(=O)OC)C=CN2C=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N HFXAVTRLAAABKN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- CAMKEDDAEGTLQE-UHFFFAOYSA-N 3-[2-[4-(hydroxycarbamoyl)anilino]pyrimidin-4-yl]-n-(2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NCCOC)C=CC2=NC(C)=C1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 CAMKEDDAEGTLQE-UHFFFAOYSA-N 0.000 claims description 2
- NDPMVITZRVBZIP-UHFFFAOYSA-N 3-[2-[4-(hydroxycarbamoyl)anilino]pyrimidin-4-yl]-n-(2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC=1N=C2C=C(C(=O)NCCOC)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 NDPMVITZRVBZIP-UHFFFAOYSA-N 0.000 claims description 2
- DAWDFYSVFPONIF-UHFFFAOYSA-N 3-[2-[4-[(2-aminophenyl)carbamoyl]anilino]pyrimidin-4-yl]-n-(2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NCCOC)C=CC2=NC(C)=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N DAWDFYSVFPONIF-UHFFFAOYSA-N 0.000 claims description 2
- SOFKWBBPHGWRDT-UHFFFAOYSA-N 3-[2-[4-[(2-aminophenyl)carbamoyl]anilino]pyrimidin-4-yl]-n-(2-methoxyethyl)-2-methylimidazo[1,2-a]pyridine-7-carboxamide Chemical compound CC=1N=C2C=C(C(=O)NCCOC)C=CN2C=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N SOFKWBBPHGWRDT-UHFFFAOYSA-N 0.000 claims description 2
- RIGBYBCOVJYBBY-UHFFFAOYSA-N 3-[2-[4-[(2-aminophenyl)carbamoyl]anilino]pyrimidin-4-yl]-n-[2-(dimethylamino)ethyl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NCCN(C)C)C=CC2=NC(C)=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N RIGBYBCOVJYBBY-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- KAAFMWRALVXNBT-UHFFFAOYSA-N 4-[(5-fluoro-4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-n-hydroxybenzamide Chemical compound C1=CC(C(=O)NO)=CC=C1NC1=NC=C(F)C(C=2N3C=CC=CC3=NC=2)=N1 KAAFMWRALVXNBT-UHFFFAOYSA-N 0.000 claims description 2
- AXCRSHHXKNOKDN-UHFFFAOYSA-N 4-[[4-(6-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=CC(Br)=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 AXCRSHHXKNOKDN-UHFFFAOYSA-N 0.000 claims description 2
- DPSUFYYVOMYUMR-UHFFFAOYSA-N 4-[[4-(6-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=CC(Cl)=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 DPSUFYYVOMYUMR-UHFFFAOYSA-N 0.000 claims description 2
- GCFVULJYFNGILX-UHFFFAOYSA-N 4-[[4-(8-fluoro-2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C(F)=CC=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 GCFVULJYFNGILX-UHFFFAOYSA-N 0.000 claims description 2
- YOZOOKSSOZEZFV-UHFFFAOYSA-N 4-[[4-[7-[(dimethylamino)methyl]-2-methylimidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=C(CN(C)C)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 YOZOOKSSOZEZFV-UHFFFAOYSA-N 0.000 claims description 2
- WHQAPHUQNJPKBH-UHFFFAOYSA-N 4-[[4-[7-[(dimethylamino)methyl]imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound C=1N=C2C=C(CN(C)C)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 WHQAPHUQNJPKBH-UHFFFAOYSA-N 0.000 claims description 2
- CFHABVVISFTSNR-UHFFFAOYSA-N 4-[[4-[7-[2-(dimethylamino)ethoxy]-2-methylimidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=C(OCCN(C)C)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 CFHABVVISFTSNR-UHFFFAOYSA-N 0.000 claims description 2
- HYQBPZLHKKSALZ-UHFFFAOYSA-N 4-[[4-[7-[2-(dimethylamino)ethylamino]-2-methylimidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]-n-hydroxybenzamide Chemical compound CC=1N=C2C=C(NCCN(C)C)C=CN2C=1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 HYQBPZLHKKSALZ-UHFFFAOYSA-N 0.000 claims description 2
- XBQQYRDGPWFCPA-UHFFFAOYSA-N 4-[ethyl-(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-n-hydroxybenzamide Chemical compound N=1C=CC(C=2N3C=CC=CC3=NC=2)=NC=1N(CC)C1=CC=C(C(=O)NO)C=C1 XBQQYRDGPWFCPA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000015790 Asparaginase Human genes 0.000 claims description 2
- 108010024976 Asparaginase Proteins 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 102000003964 Histone deacetylase Human genes 0.000 claims description 2
- 108090000353 Histone deacetylase Proteins 0.000 claims description 2
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims description 2
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010036805 Progressive massive fibrosis Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001097 amifostine Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 229960003272 asparaginase Drugs 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- 208000016361 genetic disease Diseases 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- FQEWKBXLUQYFGC-UHFFFAOYSA-N n-(2-aminophenyl)-2-fluoro-4-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]benzamide Chemical compound CC=1N=C2C=CC=CN2C=1C(N=1)=CC=NC=1NC(C=C1F)=CC=C1C(=O)NC1=CC=CC=C1N FQEWKBXLUQYFGC-UHFFFAOYSA-N 0.000 claims description 2
- ULMSXDSLTCEPGR-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[4-(2-methyl-7-morpholin-4-ylimidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl]amino]benzamide Chemical compound CC=1N=C2C=C(N3CCOCC3)C=CN2C=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N ULMSXDSLTCEPGR-UHFFFAOYSA-N 0.000 claims description 2
- LFTAFQHJYVEATC-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)pyrimidin-2-yl]amino]benzamide Chemical compound CC=1N=C2N=CC=CN2C=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N LFTAFQHJYVEATC-UHFFFAOYSA-N 0.000 claims description 2
- VKNCBSLMFJPNOP-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[4-[2-methyl-7-(2-morpholin-4-ylethoxy)imidazo[1,2-a]pyridin-3-yl]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CN2C(C=3N=C(NC=4C=CC(=CC=4)C(=O)NC=4C(=CC=CC=4)N)N=CC=3)=C(C)N=C2C=C1OCCN1CCOCC1 VKNCBSLMFJPNOP-UHFFFAOYSA-N 0.000 claims description 2
- ZZIRARNNXPVTHA-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[2-[4-(hydroxycarbamoyl)anilino]pyrimidin-4-yl]-2-methylimidazo[1,2-a]pyridine-6-carboxamide Chemical compound N12C=C(C(=O)NCCN(C)C)C=CC2=NC(C)=C1C(N=1)=CC=NC=1NC1=CC=C(C(=O)NO)C=C1 ZZIRARNNXPVTHA-UHFFFAOYSA-N 0.000 claims description 2
- FKXQSTLMJBTRNL-UHFFFAOYSA-N n-hydroxy-5-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)pyridin-2-yl]amino]-1,3,4-thiadiazole-2-carboxamide Chemical compound CC=1N=C2C=CC=CN2C=1C(C=1)=CC=NC=1NC1=NN=C(C(=O)NO)S1 FKXQSTLMJBTRNL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 229960003087 tioguanine Drugs 0.000 claims description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 239000005858 Triflumizole Substances 0.000 claims 4
- HSMVPDGQOIQYSR-KGENOOAVSA-N triflumizole Chemical compound C1=CN=CN1C(/COCCC)=N/C1=CC=C(Cl)C=C1C(F)(F)F HSMVPDGQOIQYSR-KGENOOAVSA-N 0.000 claims 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 5
- 0 ***(C*C(CC1)(*2)Nc3nccc(-c4c(*)nc(*)[n]4*)n3)CC12C(N*)=O Chemical compound ***(C*C(CC1)(*2)Nc3nccc(-c4c(*)nc(*)[n]4*)n3)CC12C(N*)=O 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 2
- WUFFEUIIXSOVBW-UHFFFAOYSA-N CC1=C(C2=NC(NNC(C3=CC=CC=C3)=O)=NC=C2)N(C=CC(C#N)=C2)C2=N1 Chemical compound CC1=C(C2=NC(NNC(C3=CC=CC=C3)=O)=NC=C2)N(C=CC(C#N)=C2)C2=N1 WUFFEUIIXSOVBW-UHFFFAOYSA-N 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8044908P | 2008-07-14 | 2008-07-14 | |
| US61/080,449 | 2008-07-14 | ||
| PCT/US2009/050577 WO2010009155A2 (en) | 2008-07-14 | 2009-07-14 | Fused heterocyclyc inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000750A Division JP2014088420A (ja) | 2008-07-14 | 2014-01-07 | ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528040A JP2011528040A (ja) | 2011-11-10 |
| JP2011528040A5 true JP2011528040A5 (enExample) | 2012-06-28 |
| JP5640006B2 JP5640006B2 (ja) | 2014-12-10 |
Family
ID=41165542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518851A Expired - Fee Related JP5640006B2 (ja) | 2008-07-14 | 2009-07-14 | ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
| JP2014000750A Withdrawn JP2014088420A (ja) | 2008-07-14 | 2014-01-07 | ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014000750A Withdrawn JP2014088420A (ja) | 2008-07-14 | 2014-01-07 | ヒストン脱アセチル化酵素および／またはサイクリン依存性キナーゼの縮合複素環式阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8124764B2 (enExample) |
| EP (1) | EP2303881A2 (enExample) |
| JP (2) | JP5640006B2 (enExample) |
| AU (1) | AU2009271019A1 (enExample) |
| CA (1) | CA2729965A1 (enExample) |
| NZ (2) | NZ590320A (enExample) |
| WO (1) | WO2010009155A2 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002534A1 (en) * | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| NZ590320A (en) | 2008-07-14 | 2012-12-21 | Gilead Sciences Inc | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| NZ590283A (en) * | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
| EP2303841A1 (en) * | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) * | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| CA2995883C (en) | 2008-12-03 | 2023-01-24 | The Scripps Research Institute | Compounds and methods for stabilizing cell cultures |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| US8283357B2 (en) * | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| CA2772488C (en) | 2009-09-11 | 2018-04-17 | Probiodrug Ag | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| NZ710405A (en) * | 2010-11-16 | 2017-04-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| JP6250403B2 (ja) | 2011-02-28 | 2017-12-20 | バイオマリン ファーマシューティカル インク | ヒストン脱アセチル化酵素阻害剤 |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
| CA2826459C (en) | 2011-03-02 | 2019-09-17 | Lead Discovery Center Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
| US8916557B2 (en) | 2011-04-19 | 2014-12-23 | Bayer Intellectual Property Gmbh | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| ES2587284T3 (es) | 2011-09-16 | 2016-10-21 | Bayer Intellectual Property Gmbh | 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9 |
| SG11201406589PA (en) | 2012-04-27 | 2014-11-27 | Eisai R&D Man Co Ltd | Method for producing 5-(difluoromethyl)pyrazine-2-carboxilic acid and production intermediate thereof |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| EP2909183B1 (en) | 2012-10-18 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
| ES2595222T3 (es) | 2012-10-18 | 2016-12-28 | Bayer Pharma Aktiengesellschaft | Derivados de 5-fluoro-N-(piridin-2-il)piridin-2-amina que contienen un grupo sulfona |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| BR112015023399A8 (pt) | 2013-03-15 | 2019-12-03 | Biomarin Pharm Inc | inibidores de hdac, seu uso e composição farmacêutica |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| ES2929576T3 (es) | 2013-10-08 | 2022-11-30 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| KR20160092018A (ko) | 2013-12-03 | 2016-08-03 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 탈아세틸화효소 저해제 및 면역조절 약물의 조합 |
| GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2687477T3 (es) * | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Inhibidor de quinasa y su uso |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| AU2015288060A1 (en) | 2014-07-07 | 2017-02-09 | Acetylon Pharmaceuticals, Inc. | Treatment of leukemia with histone deacetylase inhibitors |
| JP2017531003A (ja) | 2014-10-16 | 2017-10-19 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| AU2015356779A1 (en) | 2014-12-05 | 2017-07-13 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine for use in the treatment of lymphoma |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2980493A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma |
| WO2016150903A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
| WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| JP6947651B2 (ja) | 2015-06-26 | 2021-10-13 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ４，６−ピリミジニレン誘導体およびこれらの使用 |
| CN105111154A (zh) * | 2015-09-15 | 2015-12-02 | 上海瑞博化学有限公司 | 一种5-氨基吡嗪-2-甲酸合成新工艺 |
| CA2999931A1 (en) | 2015-09-29 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
| CN108368129B (zh) | 2015-10-08 | 2021-08-17 | 拜耳医药股份有限公司 | 改性大环化合物 |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EP3445364A4 (en) | 2016-04-19 | 2019-11-27 | Acetylon Pharmaceuticals, Inc. | HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| CN106543041A (zh) * | 2016-05-22 | 2017-03-29 | 上海清松制药有限公司 | 一种对胍基苯甲酸盐酸盐的合成方法 |
| BR112019005526A2 (pt) | 2016-10-20 | 2019-06-18 | Pfizer | agentes antiproliferativos para tratamento de pah |
| TWI720269B (zh) | 2016-11-22 | 2021-03-01 | 財團法人生物技術開發中心 | 用於調節刺蝟途徑之雜芳基胺化合物及其製法及用途 |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| AU2018214431B2 (en) | 2017-02-01 | 2021-07-29 | Aucentra Therapeutics Pty Ltd | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents |
| EP3601253B1 (en) | 2017-03-28 | 2021-09-15 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| MX388196B (es) | 2017-04-26 | 2025-03-19 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3090843A1 (en) | 2018-02-13 | 2019-08-22 | Bayer Aktiengesellschaft | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| AU2019295632B2 (en) | 2018-06-25 | 2025-03-06 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN111925366B (zh) * | 2019-05-13 | 2024-04-09 | 广东阿格蕾雅光电材料有限公司 | 一种咪唑并氮杂环化合物及其应用 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020311297A1 (en) * | 2019-07-10 | 2022-02-03 | Aucentra Therapeutics Pty Ltd | DERIVATIVES OF 4-(IMIDAZO[l,2-a]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS |
| IL289953B2 (en) * | 2019-07-24 | 2025-03-01 | Merck Patent Gmbh | 4-(Imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives |
| CN110294759B (zh) * | 2019-08-08 | 2020-05-08 | 河南省人民医院 | Hdac6选择性抑制剂 |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| EP4045506B1 (en) * | 2019-10-15 | 2025-07-23 | Aucentra Therapeutics Pty Ltd | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridin-3-yl) pyrimidin-2- amine for treating proliferative diseases and conditions |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021204626A1 (en) | 2020-04-06 | 2021-10-14 | Almirall, S.A. | Aryl and heteroaryl-carboxamide substituted heteroaryl compounds as tyk2 inhibitors |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| KR20240005019A (ko) | 2021-05-06 | 2024-01-11 | 바이엘 악티엔게젤샤프트 | 알킬아미드 치환된, 환형 이미다졸 및 살충제로서의 이의 용도 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN114591229A (zh) * | 2022-03-04 | 2022-06-07 | 苏州金蚕新材料科技有限公司 | 高效安全的2-氨基-5-卤吡啶合成2-氨基-5-羟基吡啶的方法 |
| IL321433A (en) | 2022-12-16 | 2025-08-01 | Astrazeneca Ab | Purines 2,6,9 trimethylated |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218660T3 (es) | 1996-01-16 | 2004-11-16 | Bristol-Myers Squibb Company | Inhibidores aromaticos conformacionalmente restringidos de la proteina de transferencia de trigliceridos microsomales y procedimiento. |
| US20020168761A1 (en) * | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US20040006011A1 (en) * | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| BR0014076A (pt) | 1999-09-17 | 2002-10-15 | Millennium Pharm Inc | Benzamidas e inibidores correlatos do fator xa |
| US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
| CN1308327C (zh) | 2000-04-27 | 2007-04-04 | 安斯泰来制药有限公司 | 咪唑并吡啶衍生物 |
| US6403588B1 (en) * | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| GB0103926D0 (en) * | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| CA2442654A1 (en) | 2001-04-10 | 2002-10-10 | Transtech Pharma, Inc. | Probes, systems, and methods for drug discovery |
| PL366827A1 (en) | 2001-06-21 | 2005-02-07 | Smithkline Beecham Corporation | Imidazo[1,2-a]pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
| US7196095B2 (en) | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
| EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
| US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7244740B2 (en) | 2001-10-05 | 2007-07-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| AU2002352663B2 (en) | 2001-11-13 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Cyanoalkylamino derivatives as protease inhibitors |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2003313126A (ja) | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| US20040034084A1 (en) | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| CA2388358A1 (en) | 2002-05-31 | 2003-11-30 | Voiceage Corporation | A method and device for multi-rate lattice vector quantization |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| JP2006503082A (ja) | 2002-10-17 | 2006-01-26 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20040092568A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
| EP1565446A1 (en) | 2002-11-28 | 2005-08-24 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| WO2004076452A1 (en) | 2003-02-26 | 2004-09-10 | Merck Sharp & Dohme Limited | 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| AU2004220648B2 (en) | 2003-03-06 | 2010-09-16 | Boehringer Ingelheim Animal Health USA Inc. | Antiprotozoal imidazopyridine compounds |
| ES2328819T3 (es) | 2003-04-07 | 2009-11-18 | Pharmacyclics, Inc. | Hidroxamatos como agentes terapeuticos. |
| US20050187266A1 (en) * | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
| US20050234066A1 (en) * | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
| WO2004092145A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| CA2539117A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| JP2007510671A (ja) | 2003-11-06 | 2007-04-26 | セルジーン・コーポレーション | アスベスト関連疾患および障害の治療および管理のための、ｊｎｋ阻害剤の使用方法およびそれを含む組成物 |
| US7524851B2 (en) | 2003-12-05 | 2009-04-28 | Robert Bosch Gesellschaft Fur Medizinische Forschung (Rbmf) | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy |
| WO2005060571A2 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Antiprotozoal imidazopyridine compounds |
| US7671181B2 (en) | 2004-01-16 | 2010-03-02 | Merck Sharp & Dohme Corp. | Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| KR101258504B1 (ko) | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| CA2564568A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
| US20070225293A1 (en) | 2004-04-23 | 2007-09-27 | Ab Science | Use of C-Kit Inhibitors for Treating Fibrosis |
| WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
| EP1758654A1 (en) | 2004-04-23 | 2007-03-07 | AB Science | Use of c-kit inhibitors for treating plasmodium related diseases |
| CA2566104A1 (en) | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
| WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| AU2005266312C1 (en) | 2004-07-28 | 2011-06-16 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| WO2006044509A2 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| AU2005309732A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | JNK inhibitors for treatment of CNS injury |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| MX2007007272A (es) | 2004-12-17 | 2007-07-11 | Astrazeneca Ab | 4-(4-imidazol-4-il)pirimidin-2-ilamino)benzamidas como inhibidores de cdk. |
| WO2006070943A1 (ja) | 2004-12-28 | 2006-07-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| JP2008527031A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なピロロピリジン誘導体 |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| AU2006231646A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
| BRPI0608910A2 (pt) | 2005-05-09 | 2010-02-17 | Achillion Pharmaceuticals Inc | uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada |
| JP4528918B2 (ja) | 2005-06-21 | 2010-08-25 | 学校法人 関西大学 | カルボキサミド誘導体 |
| US20060293320A1 (en) * | 2005-06-24 | 2006-12-28 | Genelabs Technologies, Inc. | Heteroaryl derivatives for treating viruses |
| US7309787B2 (en) | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| US20080207572A1 (en) | 2005-07-14 | 2008-08-28 | Ab Science | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma |
| US20100069387A1 (en) | 2005-09-07 | 2010-03-18 | Palmer Stephen S | IKK Inhibitors for the Treatment of Endometriosis |
| JP5114202B2 (ja) | 2005-09-27 | 2013-01-09 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体 |
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| AR058073A1 (es) | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| ITMI20060296A1 (it) | 2006-02-17 | 2007-08-18 | Alberto Lodolo | Dispositivo di intercettazione multifunzionale |
| EP1996233A2 (en) * | 2006-02-27 | 2008-12-03 | Gilead Colorado, Inc. | Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions |
| JP2009535333A (ja) | 2006-04-26 | 2009-10-01 | メルク エンド カムパニー インコーポレーテッド | 二置換アニリン化合物 |
| WO2008033747A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| WO2009002534A1 (en) * | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| NZ590320A (en) | 2008-07-14 | 2012-12-21 | Gilead Sciences Inc | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| NZ590283A (en) | 2008-07-14 | 2012-11-30 | Gilead Sciences Inc | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| KR20120031170A (ko) * | 2009-06-08 | 2012-03-30 | 길리애드 사이언시즈, 인코포레이티드 | 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물 |
| US8283357B2 (en) * | 2009-06-08 | 2012-10-09 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds |
-
2009
- 2009-07-14 NZ NZ590320A patent/NZ590320A/xx not_active IP Right Cessation
- 2009-07-14 US US12/502,967 patent/US8124764B2/en not_active Expired - Fee Related
- 2009-07-14 NZ NZ602832A patent/NZ602832A/en not_active IP Right Cessation
- 2009-07-14 AU AU2009271019A patent/AU2009271019A1/en not_active Abandoned
- 2009-07-14 CA CA2729965A patent/CA2729965A1/en not_active Abandoned
- 2009-07-14 WO PCT/US2009/050577 patent/WO2010009155A2/en not_active Ceased
- 2009-07-14 JP JP2011518851A patent/JP5640006B2/ja not_active Expired - Fee Related
- 2009-07-14 EP EP09790408A patent/EP2303881A2/en not_active Withdrawn
-
2014
- 2014-01-07 JP JP2014000750A patent/JP2014088420A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528040A5 (enExample) | ||
| JP7730759B2 (ja) | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 | |
| US20220282254A1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| JP2011529504A5 (enExample) | ||
| JP2011528039A5 (enExample) | ||
| JP6215315B2 (ja) | ピリジノンおよびピリダジノン誘導体 | |
| JP6339595B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| AU2013266110C1 (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| JP2020528428A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| CN104662024B (zh) | 酪氨酸激酶抑制剂 | |
| US8461162B2 (en) | Pyrazolo[1,5-a]pyrimidine derivatives | |
| TW201922291A (zh) | 組合療法 | |
| JP2021529187A (ja) | Ｎｌｒｐモジュレータ | |
| US20080153811A1 (en) | Methods of Treating Cognitive Impairment and Dementia | |
| JP2019535728A (ja) | キナーゼ阻害剤としての複素環式アミド | |
| JP5823657B1 (ja) | ドーパミンｄ１リガンドとしての複素芳香族化合物 | |
| JP2022507506A (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| JP4708438B2 (ja) | ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体 | |
| US10537560B2 (en) | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | |
| KR20150007349A (ko) | Nampt 억제제 | |
| Rombouts et al. | Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020) | |
| JP2020503339A (ja) | ピラゾロピリミジン化合物及びその使用方法 | |
| JP2021529186A (ja) | Ｎｌｒｐ調節剤 | |
| JP2022506891A (ja) | Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 | |
| JP6564394B2 (ja) | 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用 |